Cancer Immunotherapy


John serves as a co-director of the Parker Institute for Cancer Immunotherapy at Penn.  The Parker Institute represents a unique collaboration of scientists and clinicians from six universities and cancer centers across the U.S. with the shared goal of accelerating discovery and development of immune therapies for the treatment of cancers.  As part of this institute, the Wherry lab is involved in evaluating immune responses in patients undergoing immunotherapy.  The goals of these studies are to define early predictors of treatment outcomes and to identify new immune cell targets and pathways through extensive human immune cell profiling.  These studies are complemented with basic science research in pre-clinical models that aim to understand the cellular and molecular mechanisms underlying T cell exhaustion.